---
title: "PTNTD.US (PTNTD.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/PTNTD.US/news.md"
symbol: "PTNTD.US"
name: "PTNTD.US"
parent: "https://longbridge.com/zh-CN/quote/PTNTD.US.md"
datetime: "2026-03-14T21:17:12.593Z"
locales:
  - [en](https://longbridge.com/en/quote/PTNTD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PTNTD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PTNTD.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/PTNTD.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/PTNTD.US/news.md)


# PTNTD.US (PTNTD.US) — 相关新闻

### [Palamina Corp. Grants 4 Million Stock Options to Management and Advisors](https://longbridge.com/zh-CN/news/273157639.md)
*2026-01-21T01:51:35.000Z*
### [Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 | PTN Stock News](https://longbridge.com/zh-CN/news/239555182.md)
*2025-05-09T11:30:00.000Z*
> Palatin Technologies, Inc. presented promising preclinical data on its melanocortin agonists PL9654 and PL9655 for treat

### [Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News](https://longbridge.com/zh-CN/news/239464278.md)
*2025-05-09T02:19:00.000Z*
> Palatin Technologies, Inc. has announced the closing of a reduced public offering, raising approximately $1.1 million th

### [Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News](https://longbridge.com/zh-CN/news/239424906.md)
*2025-05-08T20:39:00.000Z*
> Palatin Technologies presented promising Phase 3 data for PL9643, a potential first-in-class treatment for dry eye disea

### [Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease | PTN Stock News](https://longbridge.com/zh-CN/news/238044252.md)
*2025-04-29T11:30:00.000Z*
> Palatin Technologies announced updated results from its Phase 3 MELODY-1 clinical trial for PL9643, a potential first-in